Clinical Data AZ is three for three with COPD hope tozorakimab PharmaphorumAstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.Clinical DataRespiratoryRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings. Clinical DataRespiratoryRead full story Post navigation Previous: Trump backs psychedelics for mental health in new executive orderNext: The Omnichannel Gap: Building the CRM of the Future for Patient Services Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026